Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,”
“may,” “will,” “could,” “should,” “estimates,” “projects,” “potential,” “suggests,” and similar expressions. These forward-looking statements include,
but are not limited to, statements regarding: the sufficiency of the Company’s cash, cash equivalents and short-term investments to fund its planned operations; the timing, design, initiation, enrollment, completion and data readouts of the
Company’s ongoing and planned clinical trials, including in Stage IV TNBC, HR+/HER2- breast cancer and MSS/pMMR colorectal cancer; the potential exercise of the Series A and Series B warrants issued in the August 2026 public offering and any
related proceeds; the potential therapeutic benefits and development of paxalisib, NDL2, MSETC and EVT801; the Company’s intellectual property strategy and provisional patent applications; and the activities of the Company’s
collaborators, including Sovargen.
These forward-looking statements are based on management’s current expectations and assumptions as of the date
of this press release and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to: the
preliminary nature of early-stage clinical data, which may change as more patient data become available; the risk that results of preclinical and translational studies may not be predictive of results in clinical trials in humans; risks associated
with the research and development of therapeutic programs; the timing, conduct and enrollment of the Company’s clinical trials; whether any Series A or Series B warrants will be exercised; regulatory review and approval processes; the
Company’s need to raise substantial additional capital and its ability to obtain sufficient funding to advance its programs; reliance on third-party collaborators, contract research organizations and trial sites; the Company’s ability to
obtain, maintain and protect its intellectual property; competition; general economic and market conditions; and the Company’s ability to maintain compliance with Nasdaq listing requirements.
For a more complete discussion of risks and uncertainties, please refer to the Company’s filings with the SEC, including the “Risk Factors”
section of the Company’s most recent Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future
events, or otherwise, except as required by law.